Clinical trial

Safety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients in the ICU: a Prospective, Randomized, Single-center Study

Name
2021120884Esketamine
Description
A prospective, randomized controlled study was conducted to compare the effects of esketamine combined with dexmedetomidine in the sedation and analgesia treatment of mechanically ventilated patients in the ICU on the time to awaken, time to extubation, time to mechanical ventilation, time in the ICU, and on delirium.
Trial arms
Trial start
2022-08-11
Estimated PCD
2024-12-01
Trial end
2024-12-01
Status
Recruiting
Phase
Early phase I
Treatment
Esketamine combined with dexmedetomidine
Esketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature. Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
Arms:
Esketamine combined with dexmedetomidine
Other names:
S-ketamine combined with dexmedetomidine
Dexmedetomidine
Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
Arms:
Dexmedetomidine
Other names:
Dexmedetomidine Hydrochloride Injection
Size
100
Primary endpoint
Duration of mechanical ventilation
Usually within 14 days
Eligibility criteria
Inclusion Criteria: * Mechanically ventilated with oral endotracheal intubation in the ICU; * Patients aged \>18 years and \<70 years; * Patients with expected mechanical ventilation time \>24 hours. Exclusion Criteria: * Known or suspected allergy to esketamine, dexmedetomidine, remifentanil, or propofol; * Pregnancy or lactation periods; * Obesity defined as Body Mass Index \>35kg/m2; * Extreme hemodynamic or respiratory instability due to severe burn or trauma (defined as Injury Severity Score ≥25); * Heavy drinking defined by WHO as drinking at least 60g of pure alcohol every day for men and at least 40g for women; * Terminally ill patients near death, such as patients with extensively metastatic tumor or refractory shock; * Long-term exposure to sedatives, opioid analgesics or antianxiety drugs; * Severe central nervous system disease such as cerebrovascular accidents, status epilepsy, or coma; * Acute or chronic severe liver disease (Child-Pugh class C or history of liver transplant); * Acute or chronic renal insufficiency needing dialysis; * Patients or authorized surrogates refuse to provide informed consents; * Mechanically ventilated for more than 24 hours prior to enrollment (not including the time on ventilators in the operation room).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-05-07

1 organization

2 products

5 indications

Indication
Dexmedetomidine
Indication
Ketamine
Indication
Analgesic